文献速递肝胆胰外科围术期管理与 ERAS

机器人与开放胰十二指肠切除术治疗良性和癌前病变的比较

Pancreaticoduodenectomy for benign and premalignant pancreatic and ampullary disease: is robotic surgery the better approach?
PubMed 文献 · Surg Endosc · 2022-09-22

该回顾性研究纳入2010至2020年因良性或癌前病变行胰十二指肠切除术的188例患者,其中机器人组120例、开放组68例。机器人组临床相关胰瘘、手术部位感染和90天死亡率更低,淋巴结清扫数更多,但远期并发症两组相似。

要点

  • 机器人胰十二指肠切除术可降低良性和癌前病变患者的临床相关胰瘘发生率。
  • 机器人组手术部位感染率和90天死亡率低于开放组。
  • 两组远期并发症相似,但开放组小肠梗阻及需手术干预的小肠梗阻更多。

核心结论

  • 对于良性或癌前胰腺及壶腹部疾病,机器人胰十二指肠切除术相比开放手术可降低90天死亡率、缩短住院时间并减少部分并发症。

研究设计与样本

  • 回顾性分析2010至2020年前瞻性维护的胰腺数据库,纳入连续因良性或癌前病变行胰十二指肠切除术的患者188例,其中开放组68例、机器人组120例,排除恶性组织学。

主要发现

  • 机器人组临床相关胰瘘10例(8.3%)vs 开放组24例(35.3%),p < 0.001。
  • 机器人组手术部位感染9例(7.5%)vs 开放组11例(16.2%),p = 0.024。
  • 机器人组90天死亡率1例(0.8%)vs 开放组4例(5.9%),p = 0.039。
  • 机器人组淋巴结清扫数29(IQR 21, 38)vs 开放组21(IQR 13, 34),p = 0.001。
  • 开放组小肠梗阻4例(5.9%)vs 机器人组2例(1.7%),p = 0.031;需手术干预的小肠梗阻开放组2例(2.9%)vs 机器人组0例(0.0%),p = 0.019。

临床怎么用

  • 在良性或癌前胰腺及壶腹部疾病中,机器人胰十二指肠切除术可作为开放手术的替代方案,可能降低胰瘘、手术部位感染和90天死亡率。

局限性

  • 本研究为单中心回顾性分析,样本量有限,结论需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The robotic platform is increasingly being utilized in pancreatic surgery, yet its overall merits and putative advantages remain to be adjudicated. We hypothesize that the benefits of minimally invasive pancreatic surgery are maximized in pancreatic benign and premalignant disease, in the setting of friable pancreatic tissue and small pancreatic duct. METHODS: Retrospective analysis of our prospectively maintained pancreatic database of all consecutive patients who underwent pancreaticoduodenectomy (PD) for benign or premalignant conditions between 2010 and 2020. Peri-operative outcomes and long-term complications were compared between robotic pancreaticoduodenectomy (RPD) and open pancreaticoduodenectomy (OPD). RESULTS: One hundred and eighty eight (n = 188) patients met our inclusion criteria, of which 68 were OPD and 120 RPD. Malignant histologies were excluded. There were only minor differences in baseline characteristics between the two groups. Post-operative merits of the RPD included lower clinically relevant post-operative pancreatic fistula 10 (8.3%) vs 24 (35.3%), p < 0.001, fewer surgical site infections; 9 (7.5%) vs 11 (16.2%), p = 0.024, shorter operative time, greater lymph node yield; 29 (IQR 21, 38) vs 21 (IQR 13, 34), p = 0.001, and lower 90 days mortality; 1 (0.8%) vs 4 (5.9%), p = 0.039. Rates of long-term complications were similar, exception made for a higher occurrence of small bowel obstruction (SBO) 2 (1.7%) vs 4 (5.9%), p = 0.031 and need for surgical intervention for SBO 0 (0.0%) vs 2 (2.9%), p = 0.019 in the OPD group. CONCLUSION: Our study suggests that RPD benefits include lower 90-day mortality, shorter LOS, and lower rates of selected complications compared to open pancreaticoduodenectomy.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Mungo B, Hammad A, AlMasri S, et al. Pancreaticoduodenectomy for benign and premalignant pancreatic and ampullary disease: is robotic surgery the better approach? Surg Endosc. 2022. PMID: 36138252. doi:10.1007/s00464-022-09632-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。